KR20180013422A - Composition comprising Amla extract for preventing lose of hair or promoting of hair - Google Patents
Composition comprising Amla extract for preventing lose of hair or promoting of hair Download PDFInfo
- Publication number
- KR20180013422A KR20180013422A KR1020160097134A KR20160097134A KR20180013422A KR 20180013422 A KR20180013422 A KR 20180013422A KR 1020160097134 A KR1020160097134 A KR 1020160097134A KR 20160097134 A KR20160097134 A KR 20160097134A KR 20180013422 A KR20180013422 A KR 20180013422A
- Authority
- KR
- South Korea
- Prior art keywords
- hair
- extract
- composition
- promoting
- hair growth
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 230000001737 promoting effect Effects 0.000 title claims abstract description 17
- 235000015489 Emblica officinalis Nutrition 0.000 title claims abstract description 13
- 210000004209 hair Anatomy 0.000 title abstract description 26
- 240000009120 Phyllanthus emblica Species 0.000 title 1
- 230000003779 hair growth Effects 0.000 claims abstract description 32
- 230000003658 preventing hair loss Effects 0.000 claims abstract description 13
- 244000119298 Emblica officinalis Species 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000002453 shampoo Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 235000020542 functional tea Nutrition 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 19
- 201000004384 Alopecia Diseases 0.000 abstract description 16
- 230000003078 antioxidant effect Effects 0.000 abstract description 14
- 230000003676 hair loss Effects 0.000 abstract description 13
- 208000024963 hair loss Diseases 0.000 abstract description 12
- 239000003102 growth factor Substances 0.000 abstract description 8
- 238000001727 in vivo Methods 0.000 abstract description 8
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 4
- 230000003013 cytotoxicity Effects 0.000 abstract description 4
- 244000269722 Thea sinensis Species 0.000 abstract description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 19
- 229960003632 minoxidil Drugs 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 238000005259 measurement Methods 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- 239000013642 negative control Substances 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 210000002268 wool Anatomy 0.000 description 11
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 210000003780 hair follicle Anatomy 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 8
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 8
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 241000219318 Amaranthus Species 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000002500 effect on skin Effects 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 240000001592 Amaranthus caudatus Species 0.000 description 4
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000013275 Somatomedins Human genes 0.000 description 4
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 4
- 235000012735 amaranth Nutrition 0.000 description 4
- 239000004178 amaranth Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229960004039 finasteride Drugs 0.000 description 3
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000002768 hair cell Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- 244000025012 Spondias pinnata Species 0.000 description 2
- 235000005658 Spondias pinnata Nutrition 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- VQJMAIZOEPPELO-KYGIZGOZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-(2-hydroxy-5-methylhexan-2-yl)-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol hydrochloride Chemical compound Cl.CO[C@]12CC[C@@]3(C[C@@H]1C(C)(O)CCC(C)C)[C@H]1Cc4ccc(O)c5O[C@@H]2[C@]3(CCN1CC1CC1)c45 VQJMAIZOEPPELO-KYGIZGOZSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 238000010632 SOD assay Methods 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003273 male-pattern hair loss Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- UZKQTCBAMSWPJD-UQCOIBPSSA-N trans-Zeatin Natural products OCC(/C)=C\CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-UQCOIBPSSA-N 0.000 description 1
- UZKQTCBAMSWPJD-FARCUNLSSA-N trans-zeatin Chemical compound OCC(/C)=C/CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-FARCUNLSSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 229940023877 zeatin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 탈모방지 또는 발모촉진용 조성물에 관한 것으로, 더욱 구체적으로 암라 추출물을 함유하는 탈모방지 또는 발모촉진용 조성물에 관한 것이다.The present invention relates to a composition for preventing hair loss or for promoting hair growth, and more particularly to a composition for preventing hair loss or promoting hair growth, which comprises an aqua extract.
현대사회로 가면서 탈모환자가 급격히 증가하고 있으며, 그에 대한 관심과 고민도 점점 더 심화되고 있다. 우리 몸의 두피에 있는 머리카락은 매일 0.3mm씩 자라 1년에 총 15cm가 자라며, 전체의 85% 정도가 성장하고 나머지 15%는 성장을 멈추는 것으로 알려져 있다. 빠지는 머리카락은 주로 성장을 멈춘 머리카락인데, 탈모는 빠지는 대상이 되는 성장을 멈춘 머리카락의 비율이 늘어남을 의미한다. 정상의 경우, 머리카락은 하루에 80~100개가 빠지지만, 그렇지 않은 경우 100개 이상이 빠지며, 모모세포의 힘이 약해지면서 성장기가 짧아지고 다음 성장기까지의 기간이 길어지면서 자라난 모발조차 제대로 성장하지 못하는 것을 의미한다.As we move into modern society, patients with hair loss are increasing rapidly, and interest and anxieties about it are getting worse. Hair on the scalp of our body grows by 0.3mm every day, growing 15cm in a year, 85% of the total is growing, and the remaining 15% is said to stop growing. The missing hair is mainly hair that has stopped growing, which means that the percentage of hair that has stopped growing is increasing. In normal cases, the hair falls off 80 to 100 times a day, but if it does not, more than 100 are lost. When hair growth is shortened due to weakening of the hair cells and the growth period is extended, .
탈모증(脫毛症, Baldness)란, 신체의 털, 특히 머리카락이 부족한 상태를 말한다. 탈모의 가장 큰 원인으로는 유전적인 소인과 남성호르몬, 그리고 노화현상으로 알려져 있고, 그 밖에 혈액순환장애, 과다한 스트레스, 영양불균형, 지루성 피부염, 모발 관리제품의 잘못된 사용이나 과다한 염색 탈색 등의 미용관리도 복합적으로 작용하는 것으로 알려져 있다. 유전적인 소인이 있는 사람의 모낭에서 테스토스테론이 5-α reductase에 의해 5-α dihydrotestosterone(DHT)으로 되며, 이에 의해 모낭세포의 단백 합성이 지연되어 휴지기 모낭의 비율이 증가하며 나이가 들면서 탈모가 진행된다. 국소적으로 두피의 전두부 및 두정부의 모발이 연모로 변하여 점차 가늘어지고 길이가 짧아지며 모낭이 소형화되면서 미만성으로 소실되어 가는 것을 특징으로 한다.Hair baldness (毛毛 症, Baldness) refers to the hair of the body, especially the lack of hair. The most common cause of hair loss is known as genetic swelling, male hormone, and aging phenomenon. In addition, it is known that the hair loss is caused by the blood circulation disorder, excessive stress, nutritional imbalance, seborrheic dermatitis, Are also known to work in combination. In humans with genetic predisposition, testosterone is converted to 5-α dihydrotestosterone (DHT) by 5-α reductase, thereby delaying the protein synthesis of hair follicles and increasing the percentage of dormant hair follicles. do. The hair of the front part of the scalp and the hair of the two parts of the scalp are locally changed into a soft palate and become gradually thinner and shorter in length, and the hair follicle is miniaturized and disappears diffusely.
탈모에 대한 치료는 경구복용법, 국소도포, 모발이식술을 이용하고 있으며 FDA의 허가를 취득한 약물로 Minoxidil과 Finasteride가 있다. Minoxidil은 고혈압 치료를 위한 혈관 확장제로 개발되었으나 부작용으로 다모증이 보고되면서 발모제로 개발되었다. 내복약으로 사용되는 Finasteride는 5-α reductase type Ⅱ의 활성을 억제함으로써 안드로젠의 중간 대사체인 dihydrotestosterone(DHT)의 농도를 낮추는 기전을 통하여 남성형 탈모의 치료에 이용되고 있다. 그러나 Minoxidil과 Finasteride의 효능은 사람마다 일률적이지 않고, 부작용들이 보고되고 있다. 현재 탈모증에 대한 치료는 완벽하지 않으며, 효과적이고 안전한 치료법에 대한 수요는 줄지 않고 있다. 따라서 한약재를 이용한 효과적인 탈모 예방 및 치료 물질의 개발을 통한 차별화 된 연구가 필요한 실정이다.Treatment for hair loss includes oral dosing, topical application, hair grafting, and FDA approved medications Minoxidil and Finasteride. Minoxidil was developed as a vasodilator for the treatment of hypertension, but as a side effect, it was developed as a hair growth agent. Finasteride, which is used as an oral medicine, is used for the treatment of male pattern hair loss through a mechanism of lowering the concentration of dihydrotestosterone (DHT), an intermediate metabolite of androgen, by inhibiting the activity of 5-α reductase type II. However, the efficacy of Minoxidil and Finasteride is not uniform in every person, and side effects are reported. Currently, treatment for alopecia is not perfect, and the demand for effective and safe treatments is not decreasing. Therefore, there is a need for differentiated research through prevention of effective hair loss using herbal medicines and development of therapeutic substances.
암라(Amla)는 필렘블린(phyllembiln), 갈릭산(gallic acid), 지아틴(zeatin), 비타민C 등의 다양한 영양소가 함유되어 있으며 특히, 오렌지의 20배, 사과의 160배에 해당하는 천연 비타민 C를 함유 하고 있다.Amla contains a variety of nutrients such as phyllembiln, gallic acid, zeatin and vitamin C. Particularly, natural vitamins such as 20 times of orange and 160 times of apple C.
이에, 본 발명자들은 상기 종래기술들의 문제점들을 극복하기 위하여 예의 연구노력한 결과, 본원발명의 암라 추출물의 경우, 우수한 탈모방지 또는 발모촉진 효과를 확인하고, 본 발명을 완성하게 되었다.The inventors of the present invention have made extensive efforts to overcome the problems of the prior arts. As a result, the inventors of the present invention have confirmed the excellent hair loss prevention or hair growth promoting effect and completed the present invention.
따라서, 본 발명의 주된 목적은 탈모방지 또는 발모촉진 효과가 우수한 암라 추출물을 함유하는 탈모방지 또는 발모촉진용 조성물을 제공하는 데 있다.Accordingly, it is a main object of the present invention to provide a composition for preventing hair loss or for promoting hair growth, which comprises an extract of Amara which is excellent in preventing hair loss or promoting hair growth.
본 발명의 한 양태에 따르면, 본 발명은 암라 추출물을 유효성분으로 하는 탈모방지 또는 발모촉진용 조성물을 제공한다.According to one aspect of the present invention, there is provided a hair loss preventing or hair growth promoting composition comprising an extract of Amaranth as an active ingredient.
현대사회로 가면서 탈모환자가 급격히 증가하면서 그에 대한 치료방법 또한 다양해지고 있다. 하지만, 완벽한 탈모증 치료방법에 대한 개발은 여전히 미미한 실정이다. 이에, 본 발명자들은 한약재를 이용한 효과적인 탈모 예방 및 치료물질을 연구하던 중, 암라 추출물이 탈모방지 및 발모촉진 효과가 우수하다는 것을 발견하고 본 발명을 완성하게 되었다.As the number of patients with hair loss increased rapidly in the modern society, the treatment methods for them have also been diversified. However, the development of a complete method for treating alopecia is still insignificant. Accordingly, the inventors of the present invention have found that the extract of Amaranthus exudus is excellent in the prevention of hair loss and promotion of hair growth, while studying effective hair loss preventive and therapeutic substances using herbal medicines, and completed the present invention.
본 발명에 있어서, 추출물은 종래에 사용되어진 어떠한 용매로도 추출할 수 있으며, 바람직하게는 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로 추출한 것을 특징으로 한다.In the present invention, the extract can be extracted with any solvent conventionally used, and is preferably extracted with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
또한, 상기 추출물은 종래에 사용되어진 어떠한 추출방법으로 추출할 수 있으며, 바람직하게는 암라를 용매에 2 내지 4시간 동안 침적하여 추출할 수 있다. 추출용매를 이용한 추출방법으로는 통상적인 식물의 추출방법 예를 들면, 열수 추출, 환류냉각 추출, 초음파 추출, 초임계 추출 등의 방법을 사용할 수 있다. In addition, the above extract can be extracted by any extraction method conventionally used, and preferably, Amara can be extracted by immersing in a solvent for 2 to 4 hours. As an extraction method using an extraction solvent, a conventional plant extraction method such as hot water extraction, reflux cooling extraction, ultrasonic extraction, supercritical extraction and the like can be used.
본 발명의 일 구현 예에 따른 제조방법에서, 상기 추출물은 에탄올 추출물일 수 있으나, 이에 제한되지 않는다. 추출하는 유기용매에 따라 약재의 유효성분의 추출 정도와 손실 정도가 차이날 수 있으므로, 알맞은 유기용매를 선택하여 사용하도록 한다. 추출방법은 특별히 제한되지 않고 예를 들어 열수 추출, 냉침 추출, 초음파 추출 및 환류 추출 등이 있다. 추출액을 농축할 경우에는 감압농축, 역삼투압 농축 등의 방법이 사용될 수 있다. 농축 후 건조 단계는 분무건조, 열풍건조, 동결건조, 진공건조, 감압건조, 포말건조, 고주파건조, 적외선건조 등을 포함하나 이에 제한되지 않는다In the production method according to an embodiment of the present invention, the extract may be an ethanol extract, but is not limited thereto. Depending on the organic solvent to be extracted, the degree of extraction and the degree of loss of the active ingredient in the medicinal product may differ. Therefore, an appropriate organic solvent should be selected and used. The extraction method is not particularly limited and includes, for example, hot water extraction, cold extraction, ultrasonic extraction and reflux extraction. When the extract is concentrated, methods such as concentration under reduced pressure and reverse osmosis can be used. The post-concentration drying step includes, but is not limited to, spray drying, hot air drying, freeze drying, vacuum drying, vacuum drying, foam drying, high frequency drying,
본 발명에 있어서, 상기 추출물은 농축 분말화하여 기능성 티백차의 소재로 사용되는 것을 특징으로 한다.In the present invention, the extract is concentrated and powdered to be used as a material for a functional tea bag.
본 발명에 있어서, 상기 추출물은 기능성 샴푸 및 트리트먼트의 소재로 사용되는 것을 특징으로 한다.In the present invention, the extract is used as a material for functional shampoos and treatments.
본 발명의 실험예에 따르면, 본 발명의 암라 추출물의 양모능을 확인하기 위하여 in vivo 실험을 통해 확인한 결과, 암라 추출물은 양성 대조군에 비해 양모능이 우수하거나 유사한 수준의 효과를 나타내었으며, 피부의 조직학적 변화에서도 모낭수가 양성 대조군과 유사하게 증가한 것을 확인하였다. 또한, 모발 형성에 도움을 주는 효소 활성도를 측정한 결과, 암라 추출물을 처리할 경우 효소활성이 증가되는 것을 확인하였다. 뿐만 아니라 암라 추출물은 모발성장인자의 발현을 증가시키는 것을 확인할 수 있었다. 더욱이, 두피의 혈액순환을 돕고 단백질을 파괴하는 활성산소를 줄여줘 탈모의 주원인인 DHT를 감소하는데 큰 효과를 주는 항산화물질로서 암라 추출물이 적합하다는 것을 확인할 수 있었다. 이러한 결과를 종합해 볼 때, 본원발명의 암라 추출물이 탈모방지 또는 발모촉진 효과를 나타낼 수 있음을 알 수 있다(실험예 1 내지 6 참조). According to the experimental example of the present invention, in order to confirm the bioresistance of the aqua extract of the present invention, the in vivo test revealed that the aqua extract had an excellent effect on wool activity or a similar level as that of the positive control, The number of hair follicles was increased similarly to the positive control group. As a result of measuring the enzymatic activity to aid in hair formation, it was confirmed that enzyme activity was increased when Alaa extract was treated. In addition, it was confirmed that Alaa extract increased the expression of hair growth factor. Furthermore, it was confirmed that Amla extract is suitable as an antioxidant substance which has a great effect on decreasing DHT, which is the main cause of hair loss, by reducing the active oxygen which destroys proteins and helps circulation of the scalp. These results indicate that the extract of Amaranthus according to the present invention can exhibit the effect of preventing hair loss or accelerating hair growth (see Examples 1 to 6).
또한, 본 발명의 암라 추출물은 세포독성을 나타내지 않아 티백차 소재 및 화장품 소재로 안전하다. In addition, the aqua extract of the present invention does not show cytotoxicity and is safe as a tea bag material and a cosmetic material.
본 발명에 있어서, 상기 추출물은 조성물 총 중량 대비 0.01 내지 40중량%로 포함되는 것을 특징으로 한다. 이는 기능성 티백차 제품부터 기능성 샴푸 및 트리트먼트 제품으로 개발시 각각의 기호도 및 제품 제형의 안정화를 고려하여 중량범위를 설정하였다. 샴푸 및 트리트먼트의 경우 중량범위 외 초과시 제형이 안정화되지 못하고 제형형성이 불가 할 수 있다.In the present invention, the extract is contained in an amount of 0.01 to 40% by weight based on the total weight of the composition. The weight range was set in consideration of the preference of each product and the stabilization of the product formulations when the product was developed from a functional tea bag product to a functional shampoo and a treatment product. In the case of shampoos and treatments, the formulation may not be stabilized when the weight range is exceeded, and the formulation may not be formed.
이상 설명한 바와 같이, 본원발명 암라 추출물을 함유하는 조성물은 세포독성을 나타내지 않아 안전하며, 항산화 효과가 우수하며, 모발 형성에 도움을 주는 효소 활성 및 모발성장인자 발현을 증가시킬 뿐만 아니라 in vivo에서 발모를 촉진하므로, 탈모 개선 또는 발모촉진 효과가 우수하여 탈모개선 또는 발모촉진용 티백차 조성물 또는 기능성 헤어제품으로 이용될 수 있다.As described above, the composition containing the AQUA extract of the present invention is safe because it does not exhibit cytotoxicity, has excellent antioxidative effect, increases the activity of enzymes and hair growth factors that help in hair formation, So that it can be used as a tea bag composition for improving hair loss or promoting hair growth or as a functional hair product.
도 1은 암라 추출물의 항산화능(DPPH)을 측정한 결과를 나타내는 도면이다.
도 2는 암라 추출물의 항산화능(SOD)을 측정한 결과를 나타내는 도면이다.
도 3은 암라 추출물의 모유두 세포 증식능을 측정한 결과를 나타내는 도면이다.
도 4는 포토샵을 이용하여 K값을 도출하는 방법을 나타내는 도면이다.
도 5는 in vivo에서 양모능을 측정한 결과를 나타내는 도면이다(0 day).
도 6은 in vivo에서 양모능을 측정한 결과를 나타내는 도면이다(7 day).
도 7은 in vivo에서 양모능을 측정한 결과를 나타내는 도면이다(10 day).
도 8은 in vivo에서 양모능을 측정한 결과를 나타내는 도면이다(14 day).
도 9은 in vivo에서 양모능을 측정한 결과를 나타내는 도면이다(21 day).
도 10은 양모능의 육안평가에 대한 결과를 나타내는 도면이다.
도 11은 양모능의 K값 평가에 대한 결과를 나타내는 도면이다.
도 12는 피부의 조직에서 양모능을 평가한 결과를 나타내는 도면이다.
도 13은 피부조직의 모낭수를 개수한 결과를 나타내는 도면이다.
도 14는 ALP 효소 활성을 측정한 결과를 나타내는 도면이다.
도 15는 γ?GT 효소 활성을 측정한 결과를 나타내는 도면이다.
도 16은 모발성장인자인 VEGF 변화를 측정한 결과를 나타내는 도면이다.
도 17은 모발성장인자인 IGF-1 변화를 측정한 결과를 나타내는 도면이다.
도 18은 모발성장인자인 TGF-β1 변화를 측정한 결과를 나타내는 도면이다.Fig. 1 is a diagram showing the results of measuring the antioxidative capacity (DPPH) of aqua extract.
FIG. 2 is a graph showing the results of measuring the antioxidative activity (SOD) of aqua extract.
Fig. 3 is a graph showing the measurement results of the dermal papilla cell proliferating ability of the aqua extract.
4 is a diagram showing a method of deriving a K value using Photoshop.
FIG. 5 is a graph showing the results of measurement of bovine ability in vivo (0 day).
6 is a graph showing the results of measurement of bovine ability in vivo (7 days).
Fig. 7 is a graph showing the results of measurement of bovine ability in vivo (10 days).
8 is a graph showing the results of measurement of bovine ability in vivo (14 days).
FIG. 9 is a graph showing the results of measurement of bovine ability in vivo (21 day).
Fig. 10 is a diagram showing the results of visual evaluation of bovine ability.
Fig. 11 is a diagram showing the results of evaluating the K value of bovine ability.
12 is a view showing the result of evaluating the bodily function in the tissue of the skin.
13 is a view showing the result of counting the number of hair follicles in the skin tissue.
14 is a graph showing the results of measurement of ALP enzyme activity.
15 is a graph showing the results of measurement of? - GT enzyme activity.
FIG. 16 is a graph showing the results of measuring changes in VEGF as a hair growth factor. FIG.
17 is a graph showing the results of measurement of IGF-1 change as a hair growth factor.
18 is a graph showing the results of measurement of changes in TGF-beta1 as a hair growth factor.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하기로 한다. 이들 실시예는 단지 본 발명을 예시하기 위한 것이므로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다.Hereinafter, the present invention will be described in more detail with reference to Examples. These embodiments are only for illustrating the present invention, and thus the scope of the present invention is not construed as being limited by these embodiments.
실시예Example 1: One: 암라Amla 정수 추출물의 제조 Manufacture of water extracts
본 실험에서 사용된 암라는 인도에서 수입한 제품으로 건조된 원재료를 이용하였다. 분쇄하지 않은 원료 10kg에 정수 80L를 첨가한 후, 95℃에서 1차 3시간, 2차 3시간으로 추출하였다. 이후, 60℃에서 25 brix가 될 때까지 농축하였다.The cancer used in this experiment was imported from India and used dried raw material. 80 L of purified water was added to 10 kg of the un-pulverized raw material and then extracted at 95 캜 for 3 hours for the first time and 3 hours for the second time. It was then concentrated at 60 DEG C to 25 brix.
실시예Example 2: 2: 암라Amla 주정 추출물의 제조 Manufacture of alcohol extracts
암라 주정 추출물 또한 인도에서 수입한 제품으로 분쇄하지 않은 원료 10kg에 주정 80L를 첨가한 후, 95℃에서 1차 3시간, 2차 3시간으로 추출하였다. 이후, 60℃에서 25 brix가 될 때까지 농축하였다.Amaranthus sp. Extract was also imported from India. After adding 80L of alcohol to 10kg of raw material that was not ground, it was extracted at 95 ℃ for 3 hours for 1st and 2nd for 3 hours. It was then concentrated at 60 DEG C to 25 brix.
실험예Experimental Example 1: One: 항산화능Antioxidant ability 측정 Measure
암라 추출물의 항산화능을 평가하기 위하여 DPPH(2,2-diphenyl-1- pycryl-hydrazyl) 및 Superoxide를 측정하였다. DPPH (2,2-diphenyl-1-pycryl-hydrazyl) and Superoxide were measured to evaluate the antioxidative activity of the extracts.
DPPH(2,2-diphenyl-1- pycryl-hydrazyl)는 매우 안정한 수용성 free radical로 520nm에서 특징적인 광흡수를 나타내는 보라색의 화합물이며 항산화물질과 만나게 되면 radical이 소거되면서 DPPH의 고유색인 보라색이 엷어지는 특성이 있기 때문에 이 색차를 비색 정량하여 radical 소거능을 측정하였다. 구체적으로, DPPH를 MeOH에 녹여 DPPH 용액을 제조한 후, 준비된 DPPH 용액에 암라 시료(암라 시료는 추출 농축 후 동결건조기(일신바이오베이스, FDS850)를 활용하여 24시간 동안 동결건조를 수행하고 분말화하였으며, 이에 대한 수율은 표 1에 나타내었다.) 을 1:1로 섞은 후 차광, 실온에서 30분간 방치 하였다가 520 nm에서 흡광도를 측정하였다. 또한, 양성 대조군으로는 50μM ascorbic acid를 사용하였다. 결과 값은 하기 식 1를 통해 산출하였으며, 그 결과는 도 1에 나타내었다. DPPH (2,2-diphenyl-1-pycryl-hydrazyl) is a very stable, water-soluble free radical, a violet compound that exhibits characteristic absorption at 520 nm. When it meets with antioxidants, the radical is cleared and DPPH's unique index, purple, The color difference was quantified by colorimetric determination of radical scavenging ability. Specifically, a DPPH solution was prepared by dissolving DPPH in MeOH, and then the sample was subjected to freeze-drying for 24 hours using a freeze dryer (Ilshin BioBase, FDS850) , And the yield was shown in Table 1.) was mixed with 1: 1, followed by shading and incubation at room temperature for 30 minutes. Then, the absorbance at 520 nm was measured. As a positive control, 50 μM ascorbic acid was used. The results were calculated by the following
[식 1][Formula 1]
그 결과, 도 1에서 나타나는 바와 같이, 본 발명의 암라 추출물에서 농도 의존적인 항산화능을 나타내었다. 모든 추출물 500㎍/mL(암라 정수; 72± 2.6%, 암라 주정; 75.3± 0.5%) 에서 양성대조군인 Vitamin C 50μM와 유사한 항산화효과를 보였다. 암라 주정 추출물은 저농도인 10μg/mL에서 66± 1.5%로 약 60%의 높은 항산화효과를 나타내었다. As a result, as shown in FIG. 1, the antioxidative ability of the extract of Amaranthus according to the present invention showed a concentration-dependent effect. The antioxidative effect of vitamin C was similar to that of the positive control group, Vitamin C, at 500 ㎍ / mL (Amla.; 72 ± 2.6%, Amra alcohol; 75.3 ± 0.5% Amaranthus sp. Extract showed a high antioxidative effect of about 60% at a low concentration of 10 μg / mL to 66 ± 1.5%.
또한, Superoxide의 측정은 Superoxide가 포착활성이 있는 물질이 존재 시 H2O2로 전환시키는 반응을 촉매하는 pyrogallol의 산화속도가 낮아지는 원리를 이용하여 SOD(superoxide dismutase) 활성을 측정하였다. 시험에는 SOD assay kit (Dojindo Molecular Technologies, Rockville,USA)를 사용하였으며, 흡광도 측정은 ELISA reader를 이용하였다. 구체적으로는, 먼저 시료를 10㎍/mL, 50㎍/mL, 100㎍/mL, 500㎍/mL의 농도별로 희석하여 96 well plate에 20㎕씩 분주한 후, WST working solution을 200㎕와 enzyme working solution을 20㎕를 넣고 37℃에서 20분간 incubation 한 후 450nm에서 흡광도를 측정하였다. 양성 대조군으로는 500㎍/mL trolox를 사용하였다. 결과 값은 하기 식 2를 통해 산출하였으며, 그 결과는 도 2에 나타내었다. In addition, Superoxide was measured for superoxide dismutase (SOD) activity using the principle that the oxidation rate of pyrogallol, which catalyzes the conversion of superoxide into H 2 O 2 in the presence of superoxide, is low. For the test, SOD assay kit (Dojindo Molecular Technologies, Rockville, USA) was used. Absorbance was measured by ELISA reader. Specifically, the samples were diluted to a concentration of 10 μg / mL, 50 μg / mL, 100 μg / mL, and 500 μg / mL, and 20 μL of the diluted samples were dispensed into a 96-well plate. 20 [mu] l of the working solution was incubated at 37 [deg.] C for 20 minutes and the absorbance was measured at 450 nm. As a positive control, 500 μg / mL trolox was used. The resultant value was calculated by the following
[식 2][Formula 2]
그 결과, 도 2에서 나타나는 바와 같이, 본 발명의 암라 추출물에서 항산화능이 농도 의존적으로 증가하였으며 음성 대조군 대비 유의적 차이를 보였다. 그 중 가장 높은 항산화능을 나타낸 100㎍/mL 암라 정수(64.9± 0.3), 암라 주정(65.5± 0.6)에서 양성 대조군인 500㎍/mL trolox(33.7± 0.7%) 와 SOD 활성 비교 시 2배 이상의 항산화효과를 나타내는 것을 확인하였다.As a result, as shown in FIG. 2, the antioxidant ability of the extract of Amlazoa according to the present invention increased in a concentration-dependent manner and showed a significant difference from the negative control group. The highest antioxidant activity was observed in the 100 μg / mL Amlautral (64.9 ± 0.3), Amla (65.5 ± 0.6), and the positive control, 500 μg / mL trolox (33.7 ± 0.7% Antioxidant effect.
실험예Experimental Example 2: 2: 모유두Dairy cattle 세포증식능Cell proliferation ability 확인 Confirm
인간 모유두 세포[Human follicle dermal cell, (HFDPC)]를 이용하였다. 구체적으로, 세포는 96-well 플레이트(96-well plates)에 1× 104의 세포수로 24시간 배양 후 96-well 플레이트는 희석된 화합물을 포함하는 배지를 첨가하여 1일 동안 배양한 후, MTT 시약을 활용하여 세포 증식능을 측정하였다. 그 결과는 도 3에 나타내었다.Human dermal papilla cells (HFDPC) were used. Specifically, the cells were cultured in 96-well plates at a cell number of 1 × 10 4 for 24 hours. After culturing the 96-well plate for 1 day by adding a medium containing a diluted compound, MTT reagent was used to measure cell proliferation ability. The results are shown in Fig.
MTT assay를 통한 모유두세포 증식능 측정 결과, 도 3에 나타나는 바와 같이, 양성대조군으로 사용한 minoxidil과 암라 정수, 주정 추출물은 500㎍/mL을 제외한 모든 농도에서 세포 증식능이 증가하였으며 유의적 차이를 보였다. 암라 정수, 주정 추출물 500㎍/mL의 경우에서는 세포 독성이 나타났다. 양성 대조군인 minoxidil 1㎍/mL에서 세포가 1.3배 증가하였으며 암라 정수, 주정 추출물 100㎍/mL에서 minoxidil 1μg/mL과 마찬가지로 세포증식능이 1.3배 증가하는 것을 확인하였다.As shown in FIG. 3, minoxidil, amaranth extract and alcohol extract used as a positive control group showed significant differences in cell proliferating ability at all concentrations except 500 μg / mL, as shown in the MTT assay. Ampicillin, and 500 ㎍ / mL of alcohol extract showed cytotoxicity. Cell proliferation was increased by 1.3-fold in the positive control group,
실험예Experimental Example 3: 3: C57BLC57BL /6J 마우스의 성장기 모낭 유도 평가/ 6J Mouse Growth Follicle Induction Evaluation
모발성장주기가 휴지기인 6주령의 마우스의 등쪽 털을 animalclipper (Panasonic ER1431p, Japan)로 깎아내고, 제모크림 비트(veet, Reckitt Benckiser,France)로 나머지 털을 2차에 거쳐 제거하였다. 시험약물은 2차 제모 3일 후부터 3주간 도포하였다. The dorsal hair of a 6-week-old mouse with a period of resting period of hair growth was excised with an animalclipper (Panasonic ER1431p, Japan) and the hair removed with a hair removal cream bit (veet, Reckitt Benckiser, France). The test drug was applied for 3 weeks from the third day after the second epilation.
구체적으로, 시험약물의 도포는 마우스를 ethyl ether 마취하고 시험대에 테이프로 고정시킨 후 수행하였다. 마우스가 시험물질을 핥아먹지 못하도록 도포 후 5분간 고정상태 유지하도록 하였다. 양모의 육안적 평가를 위해 0, 7, 10, 14, 21일에 ethyl ether 마취 후 각 개체 및 그룹 간 사진촬영을 진행하였으며, 판정기준은 양모정도에 따라 0-19% (-), 20-39%(± ), 40-59% (+), 60-79% (++), 0-100% (+++)로 평가하였다. 또한, 양모에 대한 수치화된 결과를 얻기 위해 포토샵 프로그램을 이용하여 이미지의 검정색을 나타내는 K값을 도출하였다. 포토샵을 이용설정한 눈금선에 마우스의 등부분을 위치하게 하여 K값을 데이터화하였다(도 4). 그 결과를 도 5 내지 도 11에 나타내었다. Specifically, application of the test drug was carried out after the mouse was anesthetized with an ether and fixed with a tape on a test stand. The mice were kept stationary for 5 minutes after application to avoid licking the test material. For the gross evaluation of wool, ethyl ether was anesthetized on the
양모에 대한 데이터를 수치화하기 위해 총 7인이 참여하여 양모 정도를 0 ~ 4점으로 평가하였다. 21일째 모든 시험약물 그룹은 음성대조군보다 높은 양모 효과를 나타내며, 특히 암라 정수 도포 그룹에서 양성대조군으로 사용한 미녹시딜과 유사한 양모효과를 나타냄을 확인하였다(도 5 내지 10 참조). In order to quantify the data on wool, a total of 7 people participated and evaluated the degree of wool as 0 ~ 4 points. On
또한, 양모의 정도를 명암(어두운 정도/ 검정색), K값으로 확인한 결과 7일째 암라 주정(19.2± 3.4)이 음성대조군 대비 유의적 증가를 나타내었다. 10일째는 모든 시험약물에서 음성 대조군(8.9± 1.3) 대비 모두 유의적 증가를 나타내었으나 특히 암라 주정(52± 4.8)이 시그마의 미녹시딜(50.3± 4.6)과 유사한 정도의 양모능을 나타내었다. 14일째부터는 시그마 미녹시딜(73.8± 2.4)과 암라 주정(76.3± 1.6)이 유사한 정도의 양모능을 나타내었으며, 시험 종료인 21일째는 암라 정수(75.3± 1.1), 암라 주정(78.1± 1.1)에서 시그마 미녹시딜(74.1± 1.3)과 유사한 양모능을 나타내는 것을 확인하였다(도 11 참조).In addition, the degree of darkness of wool (darkness / black) and the value of K were significantly increased compared with the negative control group at 7 days (19.2 ± 3.4). On the 10th day, all of the test drugs showed a significant increase compared to the negative control (8.9 ± 1.3), but in particular Amla (52 ± 4.8) showed similar bioresistance to minoxidil (50.3 ± 4.6) of Sigma. On the 14th day, Sigma minoxidil (73.8 ± 2.4) and Amara (76.3 ± 1.6) showed similar bioresistance. On the 21st day after the end of the experiment, the Amarant (75.3 ± 1.1) and Amara (78.1 ± 1.1) It was confirmed that it exhibited similar bioresistance to sigma minoxidil (74.1 ± 1.3) (see FIG. 11).
실험예Experimental Example 4: 조직학적 관찰 4: Histological observation
동물 시험 개시 10, 21일 후, 고정한 피부조직을 hematoxylinandeosin(H&E) 염색한 후 100배율에서 광학현미경으로 5mm2 면적에 대한 모낭수를 계수하였으며, 그 결과는 도 12 및 도 13에 나타내었다. After 10 and 21 days from the start of the animal test, fixed skin tissue was stained with hematoxylinandeosin (H & E), and the number of hair follicles per 5 mm 2 area was counted by an optical microscope at a magnification of 100, and the results are shown in FIG. 12 and FIG.
피부조직의 모낭수를 개수한 결과, 모든 시험약물에서 시간 경과에 따라 조직 모낭수가 증가되는 것을 확인하였다. 또한, 21일째 모든 시험약물의 조직 모낭수는 음성대조군(42± 11)과 비교 했을때 유의적 차이를 보였다. 시그마 미녹시딜 조직 모낭수(120.4± 15.5)는 3배, 현대약품 미녹시딜(76.2± 8.4)과 암라 주정(90.5± 11.3)에서 2배의 모낭이 관찰되었다.The number of hair follicles in the skin tissue was found to increase with time in all test drugs. Also, at 21 days, the number of tissue follicles of all test drugs showed a significant difference when compared to negative control (42 ± 11). Sigma minoxidil tissue hair follicles (120.4 ± 15.5) were twice as many as those of modern medicine minoxidil (76.2 ± 8.4) and Amla (90.5 ± 11.3).
실험예Experimental Example 5: 피부조직의 효소 활성도 측정 5: Measurement of enzymatic activity of skin tissue
피부조직을 절취하여 빙냉하에서 미세절편으로 만들고, 그 중 일정량을 칭량한 후, 피부조직의 4배량의 인산완충용액(phosphatebuffersolution, PBS)을 가하여 파쇄기(homogenizer)를 이용하여 균질액을 만들었다. 이 후, 균질액을 원심분리기를 이용하여 4℃에서 12,000rpm으로 20분간 원심분리하여 상층액을 자동생화학 분석기를 이용하여 alkaline phosphatase(ALP)및γ-glutamyl transpeptidase(γ-GT)를 분석하였다. 그 결과를 도 14 및 15에 나타내었다. The skin tissue was cut and made into micro slices under ice-cooling. A certain amount of the slices were weighed, and then homogenized with a homogenizer by adding phosphate buffer solution (PBS) four times the skin tissue. After that, the homogenate was centrifuged at 12,000 rpm for 20 minutes using a centrifuge at 4 ° C, and the supernatant was analyzed for alkaline phosphatase (ALP) and γ-glutamyl transpeptidase (γ-GT) using an automatic biochemical analyzer. The results are shown in Figs. 14 and 15.
ALP 효소는 모발성장의 혈관형성 지표로 알려져 있으며, 모세혈관으로 영양을 공급함으로써 양모작용을 유도한다. ALP 효소는 모발 성장기 동안은 높은 활성을 나타내고, 휴지기에서는 크게 감소한다. 이러한 피부조직내 ALP 효소를 측정한 결과, 시험물질 도포 10일 후 음성 대조군(33± 13 U/L) 대비, 양성대조군인 현대약품 미녹시딜(155.25± 32.84 U/L), 시그마 미녹시딜(156.8± 7.6 U/L)은 유의적 증가를 나타냄. 시험약물은 암라 정수(119.67±46.6 U/L)에서 음성 대조군 대비 유의적 증가를 나타내었으며, 시험물질 도포 21일 후 음성 대조군(91± 22.2 U/L) 대비, 암라 정수(132.33± 4.16 U/L)에서 유의적 증가를 나타내었다.ALP enzyme is known as an angiogenesis index of hair growth. It induces wool function by nutrition by capillary blood vessels. ALP enzymes show high activity during hair growth period and decrease significantly at rest period. The ALP enzyme in the skin tissue was measured and compared with the negative control group (33 ± 13 U / L) 10 days after the test substance application, the positive control group modern drugs minoxidil (155.25 ± 32.84 U / L), sigma minoxidil (156.8 ± 7.6 U / L) shows a significant increase. The test drug showed a significant increase from the control group (119.67 ± 46.6 U / L) compared to the negative control group. After 21 days of the test substance application, the negative control (132.33 ± 4.16 U / L), respectively.
γGT는 생체 내 산화적 스트레스와 glutathione 대사 및 세포막을 통한 아미노산과 펩타이드 흡수 및 분비에 관여하며, 증식과 분열이 활발한 세포내에서 많이 발현되고, 모발 성장기 동안은 높은 활성을 나타내고, 휴지기에서는 크게 감소한다. 실험 결과, 시험물질 도포 10일 후 음성 대조군(2.75± 1.25 U/L) 대비, 양성대조군인 현대약품 미녹시딜(37.25± 13.86 U/L), 시그마 미녹시딜(39.67± 9.87 U/L)은 유의적 증가를 나타내었고, 암라정수(12.5±2.12 U/L)에서 음성대조군 대비 유의적 증가를 나타났다.γGT is involved in the in vivo oxidative stress, glutathione metabolism, and the absorption and secretion of amino acids and peptides through the cell membrane, and is highly expressed in proliferating and dividing cells, exhibiting high activity during hair growth, and greatly decreasing in resting period . As a result, the positive control group, minoxidil (37.25 ± 13.86 U / L) and sigma minoxidil (39.67 ± 9.87 U / L), compared to the negative control group (2.75 ± 1.25 U / L) (12.5 ± 2.12 U / L) compared to the negative control group.
시험물질 도포 21일 후 음성 대조군(12.3± 2.88 U/L)대비, 현대약품 미녹시딜(24.67± 5.03 U/L), 암라 정수(23.5± 5.5 U/L)에서 유의적 증가를 나타내었다. (23.6 ± 5.5 U / L) and minoxidil (24.67 ± 5.03 U / L) compared to the negative control group (21.3 ± 2.88 U / L)
실험예Experimental Example 6: 피부조직 내 모발성장인자 측정 6: Measurement of hair growth factor in skin tissue
피부조직 내 모발성장인자인 Vascular endothelial growth factor(VEGF), insulin like growth factor(IGF)-1 및 Transforming growth factor beta 1(TGF-β1)을 측정하였다. 구체적으로, 마우스 피부 조직을 eszy-Blue™ Total RNA extraction kit (iNtRON Biotechnology, Korea)로 mRNA를 추출 후, TaqMan RNA-to-Ct™ 1-Step Kit를 사용하여 추출물과 primer (insulin like growth factor1(IGF-1), transforming growth factor beta 1(TGF-β1) 및 vascular endothelial growth factor(VEGF)를 혼합하고 StepOne 기계에서 48 ℃에서 15 분, 95 ℃에서 10 분 1 회, 95 ℃에서 15 초, 60 ℃에서 1 분으로 40회 반복하여 threshold cycle 값을 측정하였다. 그 결과는 도 16 및 도 18에 나타내었다.Vascular endothelial growth factor (VEGF), insulin like growth factor (IGF) -1 and transforming growth factor beta 1 (TGF-β1) were measured. Specifically, the mouse skin tissue was extracted with the eszy-Blue ™ Total RNA extraction kit (iNtRON Biotechnology, Korea), and then extracted with TaqMan RNA-to-Ct ™ 1-Step Kit IGF-1), transforming growth factor beta 1 (TGF-β1) and vascular endothelial growth factor (VEGF) were mixed and incubated for 15 min at 48 ° C, 1 min at 95 ° C for 15 min, And the threshold cycle value was measured by repeating 40 times for 1 minute at 20 DEG C. The results are shown in FIGS.
Vascular endothelial growth factor (VEGF)는 휴지기에 신생혈관 생성을 촉진하여 새로운 모발의 성장기로 유도하여 두피 및 모낭 세포분열에 관여하는 함으로써 대표적인 양모관련 인자이다. 21일째 피부조직 내 VEGF mRNA을 측정한 결과, 음성대조군 그룹(1.00±0.06)과 비교하였을 때 시그마 미녹시딜(2.57±0.15)과 암라 주정(4.5±0.69)에서 발현이 유의적으로 증가되는 것을 확인하였다(도 16 참조).Vascular endothelial growth factor (VEGF) is a typical wool-related factor by promoting neovascularization in the dormant period and inducing new hair growth period to participate in scalp and hair cell division. The expression of VEGF mRNA in the dermal tissues was significantly increased in Sigma minoxidil (2.57 ± 0.15) and Amara (4.5 ± 0.69) when compared to the negative control group (1.00 ± 0.06) (See Fig. 16).
또한, 피부에 존재하는 모발성장 인자인 insulin like growth factor(IGF)-1은 모발의 기능적인 활동을 촉진시켜 모낭의 세포사를 저해시킨다. 21일째 피부조직 내 IGF-1 mRNA을 측정한 결과, 그룹간의 유의적 변화는 관찰되지 않았다(도 17 참조).In addition, insulin like growth factor (IGF) -1, a hair growth factor present in the skin, promotes functional activity of the hair to inhibit hair cell death. On
Transforming growth factor beta 1(TGF-β1)은 모발의 성장기 시기에서 모발성장을 방해는 인자이다. 21일째 피부조직 내 TGF-β1 mRNA을 측정한 결과, 그룹간의 유의적 변화는 관찰되지 않았다(도 18 참조).Transforming growth factor beta 1 (TGF-β1) is a factor that interferes with hair growth in the period of hair growth. As a result of measurement of TGF-β1 mRNA in the skin tissue on the 21st day, no significant change between the groups was observed (see FIG. 18).
결론적으로, 본원발명의 암라 정수, 암라 주정은 높은 항산화 효과를 나타내며, 모유두 세포의 증식률을 유의적으로 증가시켰다. 또한, 양모능이 유의적으로 높게 나타났으며, 특히 암라 주정의 육안적, 조직학적(모낭수) 평가에서 양성대조군으로 사용한 3% 시그마 미녹시딜과 유사한 정도의 양모능을 나타내었다. 이러한 양모능은 C57BL/6J에서 모발이 성장에 영향을 주는 물질인 ALP, γ-GT 및 피부조직 내 혈관신생에 관여하는 VEGF에 의해 모발성장 주기에서 모발 재성장의 시간을 단축시키는 것으로 사료된다. In conclusion, the Amaranth gum of the present invention showed a high antioxidative effect and significantly increased the growth rate of the dermal papilla cells. In addition, wool activity was significantly higher than that of 3% Sigma minoxidil, which was used as a positive control in gross and histological evaluation (hair follicle number) of Amaranthus spp. These bioredeses are thought to shorten the time for hair regrowth in the hair growth cycle by ALP, γ-GT, and VEGF involved in the angiogenesis in the skin tissue, which affect hair growth in C57BL / 6J.
Claims (5)
A composition for preventing hair loss or promoting hair growth comprising an extract of Amla as an active ingredient.
The composition for promoting hair loss prevention or hair growth according to claim 1, wherein the aqua extract is extracted with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
[2] The composition for promoting hair loss prevention or hair growth according to claim 1, wherein the extract is concentrated and powdered to be used as a material for a functional tea bag.
The composition for preventing hair loss or promoting hair growth according to claim 1, wherein the extract is used as a material for functional shampoos and treatments.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160097134A KR20180013422A (en) | 2016-07-29 | 2016-07-29 | Composition comprising Amla extract for preventing lose of hair or promoting of hair |
PCT/KR2017/008104 WO2018021847A1 (en) | 2016-07-29 | 2017-07-27 | Composition for preventing hair loss or stimulating hair growth, containing amla extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160097134A KR20180013422A (en) | 2016-07-29 | 2016-07-29 | Composition comprising Amla extract for preventing lose of hair or promoting of hair |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20180013422A true KR20180013422A (en) | 2018-02-07 |
Family
ID=61017171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160097134A KR20180013422A (en) | 2016-07-29 | 2016-07-29 | Composition comprising Amla extract for preventing lose of hair or promoting of hair |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20180013422A (en) |
WO (1) | WO2018021847A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220156274A (en) | 2021-05-18 | 2022-11-25 | (주)뷰리클 | Cosmetic composition comprising natural herb complex extract as effective component |
KR102481945B1 (en) * | 2022-05-10 | 2022-12-29 | 주식회사 네이처팩토리 | Cosmetic composition for scalp and hair containing natural complex extract as an active ingredient |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100664400B1 (en) * | 2005-07-01 | 2007-01-04 | 동아제약주식회사 | Composition for preventing the hair from falling out |
KR100780577B1 (en) * | 2005-12-23 | 2007-11-29 | 주식회사 바이웰 | Composition for growing hair and preventing fall-out of hair |
KR100827355B1 (en) * | 2007-06-18 | 2008-05-06 | 박은주 | Hair shampoo for health of head skin |
KR101547920B1 (en) * | 2012-12-05 | 2015-08-27 | 강원도립대학산학협력단 | Natural shampoo bar for preventing and treating of scalp and hair, and manufacturing method thereof |
KR101780692B1 (en) * | 2015-06-24 | 2017-09-25 | 주식회사 티젠 농업회사법인 | Composition comprising natural mixture extract for preventing lose of hair or promoting growth of hair |
-
2016
- 2016-07-29 KR KR1020160097134A patent/KR20180013422A/en unknown
-
2017
- 2017-07-27 WO PCT/KR2017/008104 patent/WO2018021847A1/en active Application Filing
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220156274A (en) | 2021-05-18 | 2022-11-25 | (주)뷰리클 | Cosmetic composition comprising natural herb complex extract as effective component |
KR102481945B1 (en) * | 2022-05-10 | 2022-12-29 | 주식회사 네이처팩토리 | Cosmetic composition for scalp and hair containing natural complex extract as an active ingredient |
Also Published As
Publication number | Publication date |
---|---|
WO2018021847A1 (en) | 2018-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Junlatat et al. | Hair growth‐promoting effect of Carthamus tinctorius floret extract | |
KR102257524B1 (en) | Cosmetic composition for improving skin condition Centella Asiatica―derived exsome having skin calming and regeneration | |
KR20170000490A (en) | Composition comprising natural mixture extract for preventing lose of hair or promoting growth of hair | |
KR101194767B1 (en) | Cosmetic compound containing green apple for pore-minimizing and inhibiting secretion of sebum | |
Pakravan et al. | Cosmeceutical effect of ethyl acetate fraction of Kombucha tea by intradermal administration in the skin of aged mice | |
KR20130088997A (en) | Cosmetic composition for hair growth and restoration from caviar extracts and its fermentation | |
Liang et al. | Hair growth-promotion effects and antioxidant activity of the banana flower extract HappyAngel®: double-blind, placebo-controlled trial | |
KR101965595B1 (en) | Composition for prevention of losing hair or promotion of growing hair | |
KR20180013422A (en) | Composition comprising Amla extract for preventing lose of hair or promoting of hair | |
KR101615314B1 (en) | Composition for prevention of hair loss and promotion of hair growth containing extract of feremented herbal medicine | |
KR101894175B1 (en) | Composition for Cosmetics Containing Mixed Extracts of Propolis, Moringa and Morus alba L | |
Pekmezci et al. | Proprietary herbal extract downregulates the gene expression of IL-1α in HaCaT Cells: Possible implications against nonscarring alopecia | |
KR20180013423A (en) | Composition comprising Hibiscus sabdariffa L. extract for preventing lose of hair or promoting of hair | |
CN112089638B (en) | Composition for inhibiting melanin synthesis | |
KR102343705B1 (en) | Cosmetic composition containing natural complex extracts as active ingredient | |
Kim et al. | Platycarya strobilacea S. et Z. extract has a high antioxidant capacity and exhibits hair growth-promoting effects in male C57BL/6 mice | |
US9610236B2 (en) | Cosmetic use of Queuine | |
KR20210024357A (en) | Antioxidant and moisturizing cosmetic composition containing mixed extracts including Prunus yedoensis flower, Peach tree flower and Chrysanthemum flower extract | |
KR101616284B1 (en) | Anti-skin aging or Anti-wrinkle Cosmetic composition comprising specific herbal extracts | |
KR20210009178A (en) | Compositions containing Gastrodia extracts | |
KR101724870B1 (en) | Wnt/-catenin Activity promoting composition of Wnt/-catenin signaling with Anthriscus sylvestris Hoffm extract | |
KR20180094820A (en) | Composition for prevention of losing hair or promotion of growing hair comprising bean extract | |
KR101247239B1 (en) | Compositon for Prevention of Hair Loss or Stimulation of Hair Growth Containing Ecklonia cava Extracts Having Diekol or Diekol derived from Ecklonia cava | |
KR20190032857A (en) | Composition comprising Amla and Hibiscus extracts for preventing lose of hair or promoting of hair | |
KR20150108088A (en) | Composition comprising Trapa japonica FLEROV extract for improving or skin-aging stress-induced skin |